Figure 4:

Model of ATTR-CA progression over time. Myocardial amyloid infiltration occurs before clinically manifested changes in ejection fraction, cardiac biomarkers, and renal function. The ideal emerging therapeutic window for novel therapies is hypothesized to be before significant organ dysfunction has occurred and before rapid and potentially irreversible declines in functional capacity. The relative scale specific to each factor and time course are not proportional. (From Circulation. 2019 Jul 2;140(1):27–30).